Literature DB >> 2447506

Characterization of ribosomal frameshifting in HIV-1 gag-pol expression.

T Jacks1, M D Power, F R Masiarz, P A Luciw, P J Barr, H E Varmus.   

Abstract

Based on precedents from other retroviruses, the precursor of the human immunodeficiency virus (HIV-1) reverse transcriptase is predicted to be a polyprotein with a relative molecular mass (Mr) of 160,000 (160K) encoded by both the viral pol gene and the upstream gag gene. These two genes lie in different translational reading frames, with the 3' end of gag overlapping the 5' end of pol by 205 or 241 nucleotides. Thus, production of the gag-pol fusion protein would require either messenger RNA processing or translational frameshifting. The latter mechanism has been shown in the synthesis of the gag-pol proteins of two other retroviruses, Rous sarcoma virus (RSV) and mouse mammary tumour virus (MMTV). Here we report that translation of HIV-1 RNA synthesized in vitro by SP6 RNA polymerase yields significant amounts of a gag-pol fusion protein, indicating that efficient ribosomal frameshifting also occurs within the HIV-1 gag-pol overlap region. Site-directed mutagenesis and amino-acid sequencing localized the site of frameshifting to a UUA leucine codon near the 5' end of the overlap.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2447506     DOI: 10.1038/331280a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  406 in total

1.  Translational suppressors and antisuppressors alter the efficiency of the Ty1 programmed translational frameshift.

Authors:  C L Burck; Y O Chernoff; R Liu; P J Farabaugh; S W Liebman
Journal:  RNA       Date:  1999-11       Impact factor: 4.942

2.  The frameshift signal of HIV-1 involves a potential intramolecular triplex RNA structure.

Authors:  Jonathan D Dinman; Sara Richter; Ewan P Plant; Ronald C Taylor; Amy B Hammell; Tariq M Rana
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-16       Impact factor: 11.205

3.  Structural analysis of the -1 ribosomal frameshift elements in giardiavirus mRNA.

Authors:  L Li; A L Wang; C C Wang
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

4.  Expression and processing of proteins encoded by the Saccharomyces retrotransposon Ty5.

Authors:  P A Irwin; D F Voytas
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

5.  The dimer interfaces of protease and extra-protease domains influence the activation of protease and the specificity of GagPol cleavage.

Authors:  Steven C Pettit; Sergei Gulnik; Lori Everitt; Andrew H Kaplan
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

Review 6.  An evolutionary perspective on protein moonlighting.

Authors:  Shelley D Copley
Journal:  Biochem Soc Trans       Date:  2014-12       Impact factor: 5.407

7.  The nature of the N-terminal amino acid residue of HIV-1 RNase H is critical for the stability of reverse transcriptase in viral particles.

Authors:  Guney Boso; Claes Örvell; Nikunj V Somia
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

8.  The lytic transcriptome of Kaposi's sarcoma-associated herpesvirus reveals extensive transcription of noncoding regions, including regions antisense to important genes.

Authors:  Sanjay Chandriani; Yiyang Xu; Don Ganem
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

9.  Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease.

Authors:  Steve C Pettit; Gavin J Henderson; Celia A Schiffer; Ronald Swanstrom
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  Study of antigen-processing steps reveals preferences explaining differential biological outcomes of two HLA-A2-restricted immunodominant epitopes from human immunodeficiency virus type 1.

Authors:  W M Cohen; A Bianco; F Connan; L Camoin; M Dalod; G Lauvau; E Ferriès; B Culmann-Penciolelli; P M van Endert; J P Briand; J Choppin; J G Guillet
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.